{
    "clinical_study": {
        "@rank": "142794", 
        "arm_group": [
            {
                "arm_group_label": "Moderate Hepatic Insufficiency", 
                "arm_group_type": "Experimental", 
                "description": "Participants with moderate hepatic insufficiency will receive a single 100 mg dose of MK-4618."
            }, 
            {
                "arm_group_label": "Healthy", 
                "arm_group_type": "Experimental", 
                "description": "Participants who are healthy will receive a single 100 mg dose of MK-4618."
            }, 
            {
                "arm_group_label": "Mild Hepatic Insufficiency", 
                "arm_group_type": "Experimental", 
                "description": "Participants with mild hepatic insufficiency will receive a single 100 mg dose of MK-4618."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will investigate the pharmacokinetics of a single oral dose of MK-4618\n      administered to participants with moderate hepatic insufficiency and healthy participants\n      matched for age, gender, and body mass index (BMI). Participants may be enrolled with mild\n      hepatic insufficiency."
        }, 
        "brief_title": "A Single-Dose Study of the Pharmacokinetics of MK-4618 in Patients With Hepatic Insufficiency (MK-4618-013)", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Overactive Bladder", 
        "condition_browse": {
            "mesh_term": [
                "Urinary Bladder, Overactive", 
                "Hepatic Insufficiency"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is planned to be conducted in two parts. Part 1 of the study will include\n      participants with moderate hepatic insufficiency and healthy participants. If Part 2 is\n      conducted, Part 2 of the study will include participants with mild hepatic insufficiency."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        For both healthy participants and participants with hepatic insufficiency:\n\n          -  Continuous non-smokers who haven't used nicotine-containing products for\n\n        at least 3 months prior to study drug administration\n\n          -  Body mass index (BMI) \u226439 kg/m^2\n\n          -  Good health based on medical history, physical examination, vital signs,\n\n        laboratory safety tests, and electrocardiogram (ECG)\n\n          -  Females of childbearing potential must be sexually inactive for 14 days\n\n        prior to study drug administration and throughout study or use acceptable\n\n        birth control method\n\n          -  Females of non-childbearing potential must have undergone an acceptable\n\n        sterilization procedure at least 6 months prior to Day 1 of study or be\n\n        postmenopausal with amenorrhea for at least 1 year prior to Day 1\n\n          -  Non-vasectomized males must agree to use a condom with spermicide or\n\n        abstain from sexual intercourse during the trial and for 3 months after\n\n        study drug administration\n\n        For participants with hepatic insufficiency only:\n\n          -  Diagnosis of chronic, stable, hepatic insufficiency\n\n          -  For Part 1 Participants: Child-Pugh scale range from 7 to 9\n\n          -  For Part 2 Participants: Child-Pugh scale range from 5 to 6\n\n        Exclusion Criteria\n\n          -  History or presence of significant cardiovascular, pulmonary, renal,\n\n        hematologic, gastrointestinal, endocrine, immunologic, dermatologic,\n\n        neurological disease\n\n          -  History or presence of alcoholism or drug abuse within the past 2 years\n\n          -  Females who are pregnant or lactating\n\n          -  Use of any drugs or substances known to be significant inhibitors or\n\n        inducers of cytochrome P3A (CYP3A) enzymes and/or permeability glycoprotein\n\n        (P-gp)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01737684", 
            "org_study_id": "4618-013"
        }, 
        "intervention": {
            "arm_group_label": [
                "Moderate Hepatic Insufficiency", 
                "Healthy", 
                "Mild Hepatic Insufficiency"
            ], 
            "description": "50 mg tablet, oral", 
            "intervention_name": "MK-4618", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "July 23, 2013", 
        "number_of_arms": "3", 
        "official_title": "A Two-Part, Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-4618 in Patients With Hepatic Insufficiency", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Area under the concentration time curve from 0 to infinity (AUC0-\u221e) after a single oral dose of 100 mg of MK-4618", 
            "safety_issue": "No", 
            "time_frame": "Predose to 336 hours post-dose"
        }, 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01737684"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Apparent clearance (CL/F), calculated as Dose/AUC0-\u221e, after a single oral dose of 100 mg of MK-4618", 
                "safety_issue": "No", 
                "time_frame": "Predose to 336 hours post-dose"
            }, 
            {
                "measure": "Apparent volume of distribution during the terminal phase (Vd/F) after a single oral dose of 100 mg of MK-4618", 
                "safety_issue": "No", 
                "time_frame": "Predose to 336 hours post-dose"
            }, 
            {
                "measure": "Maximum observed plasma drug concentration (Cmax) after a single oral dose of 100 mg of MK-4618", 
                "safety_issue": "No", 
                "time_frame": "Predose to 336 hours post-dose"
            }, 
            {
                "measure": "Time to maximum observed plasma drug concentration (Tmax) after a single oral dose of 100 mg of MK-4618", 
                "safety_issue": "No", 
                "time_frame": "Predose to 336 hours post-dose"
            }, 
            {
                "measure": "Apparent terminal half-life (t\u00bd) after a single oral dose of 100 mg of MK-4618", 
                "safety_issue": "No", 
                "time_frame": "Predose to 336 hours post-dose"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}